Biora Therapeutics, Inc. (BIOR)

USD 0.65

(9.59%)

Market Cap (In USD)

2.92 Million

Revenue (In USD)

4000.00

Net Income (In USD)

-124.11 Million

Avg. Volume

205.89 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.26-19.9
PE
-
EPS
-
Beta Value
1.276
ISIN
US74319F3055
CUSIP
74319F107
CIK
1580063
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Aditya P. Mohanty M.B.A.
Employee Count
-
Website
https://www.bioratherapeutics.com
Ipo Date
2020-06-19
Details
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.